(Oxymorphone Hydrochloride Injection, USP) CII
(Oxymorphone Hydrochloride Suppositories, USP)
NUMORPHAN (oxymorphone hydrochloride, USP), a semi-synthetic opioid substitute for morphine, is a potent analgesic.
NUMORPHAN Suppository is indicated for the relief of moderate to severe pain.
NUMORPHAN Injection is indicated for the relief of moderate to severe pain. It is also indicated for preoperative medication, for support of anesthesia, for obstetrical analgesia, and for relief of anxiety in patients with dyspnea associated with pulmonary edema secondary to acute left ventricular dysfunction.
Media Articles Related to Numorphan (Oxymorphone)
Getting in Front of Back Pain
Source: Yahoo Health News [2014.04.12]
SATURDAY, April 12, 2014 (HealthDay News) -- Even though back pain affects nearly 10 million Americans a year, there's a lot you can do to avoid the problem, an expert says. It begins with healthy habits, including not smoking along with maintaini...
14th Annual Strategic Project and Portfolio Management for Pharma, 26-28 January 2015, Spain
Source: Conferences News From Medical News Today [2014.04.11]
14th Annual Strategic Project and Portfolio Management for Pharma, 26-28 January 2015, SpainThe 14th Annual Conference on Strategic Project & Portfolio Management for Pharma will look at how...
Scripps Florida Scientists win grant to study how exposure to prescription pain medication in the womb affects developing brain
Source: Pregnancy / Obstetrics News From Medical News Today [2014.04.11]
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded a $472,500 Cutting Edge Basic Research Award (CEBRA) by the National Institute on Drug Abuse (NIDA) of...
A Young Woman With Unilateral Eye Pain and Erythema
Source: Medscape Ophthalmology Headlines [2014.04.10]
A 30-year-old woman presents with right eye pain, air and light sensitivity, and redness. What is your differential diagnosis, and what would you do next?
Certain Prescription Painkillers Tied to Higher Risk of Irregular Heartbeat: Study
Source: MedicineNet Atrial Fibrillation Specialty [2014.04.10]
Title: Certain Prescription Painkillers Tied to Higher Risk of Irregular Heartbeat: Study
Category: Health News
Created: 4/9/2014 12:35:00 PM
Last Editorial Review: 4/10/2014 12:00:00 AM
Published Studies Related to Numorphan (Oxymorphone)
Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users. [2011.05]
OBJECTIVE: To compare the subjective effects of oxymorphone extended release (OM-ER) versus oxycodone controlled release (OC-CR)... CONCLUSIONS: At equianalgesic doses, single oral intact OM-ER produced lower positive, negative, and balance subjective effects than OC-CR, indicating that analgesic potency may not necessarily be reflected in subjective/objective effects.
Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone. [2010.11]
BACKGROUND: Opioids provide effective pain control, yet have risks including adverse events (AEs) (e.g., constipation, nausea/vomiting, sedation) and cognitive/psychomotor effects. OBJECTIVE: To compare cognitive and psychomotor effects of oxymorphone extended release (OM-ER) versus oxycodone controlled release (OC-CR)... CONCLUSION: Single oral intact low and high doses of OM-ER produced less cognitive and psychomotor impairment plus less sedation than equianalgesic OC-CR in this exploratory study. ClinicalTrials.gov registration NCT00955110.
Long-term tolerability and effectiveness of oxymorphone extended release in patients with cancer. [2010.05]
OBJECTIVE: To evaluate the long-term safety, tolerability, and effectiveness of oxymorphone extended release (ER) in patients with cancer-related pain... CONCLUSIONS: In these patients with pain related to cancer, oxymorphone ER was generally well tolerated and provided stable long-term pain control.
The pain quality response profile of oxymorphone extended release in the treatment of low back pain. [2009.02]
OBJECTIVE: In controlled trials of analgesics, the primary outcome variable is most often a measure of global pain intensity. However, because pain is associated with a variety of pain sensations, the effects of analgesic treatments on different sensations could go undetected if specific pain qualities are not assessed...
Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use. [2009.02]
OBJECTIVE: This study assessed the potential effects of age, sex, and prior opioid use on the response to oxymorphone extended release (ER) in patients with moderate to severe chronic low back pain... CONCLUSION: In the enriched population of patients who successfully titrated to oxymorphone ER, oxymorphone ER was effective and generally well tolerated, independent of patients' age, sex, or previous opioid use.
Clinical Trials Related to Numorphan (Oxymorphone)
Effect of Extended-Release Oxymorphone Taking With or Without Food on Cognitive Functioning [Recruiting]
The purpose of the study is to determine whether extended-release oxymorphone hydrochloride
taken orally with a high-fat meal, generating an approximately 50% higher Cmax, impacts
cognitive functioning, using Cambridge Neuropsychological Test Automated Battery (CANTAB)
tests, to a greater extent than when taking under conditions of fasting.
A Pilot Study of Ultra Rapid Opioid Rotation and Titration of Oxymorphone [Recruiting]
This project will explore the safety and feasibility of performing a successful intravenous
patient controlled analgesia (IV PCA) Oxymorphone titration and conversion to oral ER
Oxymorphone (extended release or OPANA ER) in the outpatient setting.
Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects [Recruiting]
Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects [Recruiting]
Patients will convert from current opioid to Oxymorphone ER and undergo titration. During
the Titration Period, subjects will receive daily oxymorphone Extended Release tablets(s)
every 12 hours. Dosing adjustments will be based on the review of the subject's pain
scores. Oxymorphone IR 5 mg will be provided to be used as supplemental "breakthrough" pain
medication (as needed). Titration Period will end when the fixed dose of study medication
is tolerated and the subject achieves adequate analgesia. Subjects will then proceed to the
open-label 3-month maintenance period on the fixed dose of study medication established
during the Titration Period.
Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects. [Recruiting]
When post-operative parenteral analgesia is discontinued, oral dosing with study medication
may begin once the subject has developed a moderate level of pain as defined by a 100 mm VAS
(pain intensity score greater than or equal to 40).